17
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Comparison between multiparametric MRI with and without post - contrast sequences for clinically significant prostate cancer detection

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          ABSTRACT

          Background:

          Dynamic-contrast enhanced (DCE) sequence is used to increase detection of small lesions, based on increased vascularization. However, literature is controversy about the real incremental value of DCE in detection of clinically significant (CS) prostate cancer (PCa), since absence of enhancement does not exclude cancer, and enhancement alone is not definitive for tumor. Purpose: To test the hypothesis that DCE images do not increase CS PCa detection on MRI prior to biopsy, comparing exams without and with contrast sequences. Material and Materials and Methods: All men who come to our institution to perform MRI on a 3T scanner without a prior diagnosis of CS PCa were invited to participate in this study. Reference standard was transrectal prostate US with systematic biopsy and MRI/US fusion biopsy of suspicious areas. Radiologists read the MRI images prospectively and independently (first only sequences without contrast, and subsequently the entire exam) and graded them on 5-points scale of cancer suspicion.

          Results:

          102 patients were included. Overall detection on biopsy showed CS cancer in 43 patients (42.2%), clinically non-significant cancer in 11 (10.8%) and negative results in 48 patients (47%). Positivities for CS PCa ranged from 8.9% to 9.8% for low suspicion and 75.0% to 88.9% for very high suspicion. There was no statistical difference regarding detection of CS PCa (no statistical difference was found when compared accuracies, sensitivities, specificities, PPV and NPV in both types of exams). Inter-reader agreement was 0.59.

          Conclusion:

          Exams with and without contrast-enhanced sequences were similar for detection of CS PCa on MRI.

          Related collections

          Most cited references25

          • Record: found
          • Abstract: found
          • Article: not found

          Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer.

          We examined preoperative clinical and pathologic parameters in men with clinical stage T1c disease who underwent radical prostatectomy and correlated these findings with the pathologic extent of disease in the surgical specimen in an attempt to identify a subset of patients with potentially biologically insignificant tumor who might be followed up without immediate treatment. A case series of 157 consecutive men who underwent radical prostatectomy for clinical stage T1c disease compared with 64 similarly treated clinical stage T1a cancers (incidental minimal cancers found on transurethral resection of prostate) and 439 clinical stage T2 (palpable) cancers. Pathologic stage, grade, and margins; tumor volume; and tumor location. Sixteen percent of tumors were insignificant ( 0.5 cm3 or capsular penetration, with a Gleason score or = 7 or positive margins, seminal vesicles, or lymph nodes). These findings are intermediate between those found in clinical stage T1a and stage T2 disease. The following parameters were not predictive of tumor extent: age, reason for evaluation, method of detection, and transrectal ultrasound. The best model predicting insignificant tumor was prostate-specific antigen (PSA) density less than 0.1 ng/mL per gram and no adverse pathologic findings on needle biopsy, or PSA density of 0.1 to 0.15 ng/mL per gram, with a low- to intermediate-grade cancer smaller than 3 mm found in only one needle biopsy core specimen. The positive predictive value of the model was 95%, with a negative predictive value of 66%. We accurately predicted 73% of cases with insignificant tumor. Eighty-four percent of nonpalpable prostate cancers diagnosed by screening techniques are significant tumors and warrant definitive therapy. However, 16% are insignificant. Serum PSA level, PSA density, and needle biopsy pathologic findings are accurate predictors of tumor extent. It may be reasonable to follow up some patients whose tumors are most likely insignificant with serial PSA measurements and repeated biopsies.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Quality-of-life effects of prostate-specific antigen screening.

            After 11 years of follow-up, the European Randomized Study of Screening for Prostate Cancer (ERSPC) reported a 29% reduction in prostate-cancer mortality among men who underwent screening for prostate-specific antigen (PSA) levels. However, the extent to which harms to quality of life resulting from overdiagnosis and treatment counterbalance this benefit is uncertain. On the basis of ERSPC follow-up data, we used Microsimulation Screening Analysis (MISCAN) to predict the number of prostate cancers, treatments, deaths, and quality-adjusted life-years (QALYs) gained after the introduction of PSA screening. Various screening strategies, efficacies, and quality-of-life assumptions were modeled. Per 1000 men of all ages who were followed for their entire life span, we predicted that annual screening of men between the ages of 55 and 69 years would result in nine fewer deaths from prostate cancer (28% reduction), 14 fewer men receiving palliative therapy (35% reduction), and a total of 73 life-years gained (average, 8.4 years per prostate-cancer death avoided). The number of QALYs that were gained was 56 (range, -21 to 97), a reduction of 23% from unadjusted life-years gained. To prevent one prostate-cancer death, 98 men would need to be screened and 5 cancers would need to be detected. Screening of all men between the ages of 55 and 74 would result in more life-years gained (82) but the same number of QALYs (56). The benefit of PSA screening was diminished by loss of QALYs owing to postdiagnosis long-term effects. Longer follow-up data from both the ERSPC and quality-of-life analyses are essential before universal recommendations regarding screening can be made. (Funded by the Netherlands Organization for Health Research and Development and others.).
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis.

                Bookmark

                Author and article information

                Journal
                Int Braz J Urol
                Int Braz J Urol
                ibju
                International Brazilian Journal of Urology : official journal of the Brazilian Society of Urology
                Sociedade Brasileira de Urologia
                1677-5538
                1677-6119
                Nov-Dec 2018
                Nov-Dec 2018
                : 44
                : 6
                : 1129-1138
                Affiliations
                [1 ]Departamento de Radiologia e Diagnóstico por Imagem, Hospital Israelita Albert Einstein, SP, Brasil
                [2 ]Ecoar Medicina Diagnóstica, Lourdes, Belo Horizonte, MG, Brasil
                [3 ]Departamento de Intervenção Guiada por Imagens, Hospital Israelita Albert Einstein, SP, Brasil
                [4 ]Departamento de Patologia, Hospital Israelita Albert Einstein, SP, Brasil
                [5 ]Departamento de Urologia, Hospital Israelita Albert Einstein, SP, Brasil
                Author notes
                Correspondence address: Thais Caldara Mussi, MD, Departamento de Radiologia e Diagnóstico por Imagem, Hospital Israelita Albert Einstein, Av. Albert Einstein, n° 627 São Paulo, SP, 05652-900, Brasil Telephone: + 55 11 2151-4271 E-mail: thaiscaldara@ 123456gmail.com

                CONFLICT OF INTEREST

                None declared.

                Article
                S1677-5538.IBJU.2018.0102
                10.1590/S1677-5538.IBJU.2018.0102
                6442176
                30325611
                603dd2b6-d65f-484c-97b9-26efca6cc465

                This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

                History
                : 16 February 2018
                : 17 June 2018
                Page count
                Figures: 1, Tables: 3, Equations: 0, References: 41, Pages: 10
                Categories
                Original Article

                magnetic resonance imaging,prostatic neoplasms,men
                magnetic resonance imaging, prostatic neoplasms, men

                Comments

                Comment on this article